Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial
| Autor: | Alberto Zanchetti, Willem H. Birkenhäger, Jaakko Tuomilehto, Gastone Leonetti, Patricia McCormack, Peter W. de Leeuw, Jan A. Staessen, Cinzia Sarti, Eoin O'Brien, Jose L. Rodicio, C Nachev, Joseph B. Rosenfeld, Françoise Forette, Christopher J. Bulpitt, John Webster, Hilde Celis, Astrid E. Fletcher, Lutgarde Thijs, Yair Yodfat, Robert Fagard |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Dihydropyridines medicine.medical_specialty Time Factors Physiology Systolic hypertension Myocardial Infarction Diastole Blood Pressure Placebo Drug Administration Schedule law.invention Hydrochlorothiazide Double-Blind Method Enalapril Randomized controlled trial law Internal medicine Diabetes Mellitus Internal Medicine medicine Humans Stroke Antihypertensive Agents Aged Heart Failure business.industry Incidence Nitrendipine Calcium Channel Blockers medicine.disease Surgery Europe Survival Rate Treatment Outcome Blood pressure Hypertension Linear Models Cardiology Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Hypertension. 22:847-857 |
| ISSN: | 0263-6352 |
| Popis: | Background To assess the impact of immediate versus delayed anti hypertensive treatment on the outcome of older patients with isolated systolic hypertension, we extended the double- blind placebo-controlled Systolic Hypertension in Europe (Syst- Eur) trial by an open-label follow-up study lasting 4 years. Methods The Syst-Eur trial included 4695 randomized patients with minimum age of 60 years and an untreated blood pressure of 160-219 mmHg systolic and below 95 mmHg diastolic. The double- blind trial ended after a median follow-up of 2.0 years (range 1-97 months). Of 4409 patients still alive, 3517 received open- label treatment consisting of nitrendipine (10-40 mg daily) with the possible addition of enalapril (5-20 mg daily), hydrochlorothiazide (12.5 - 25 mg daily), or both add-on drugs. Non-participants (n = 892) were also followed up. Results Median follow-up increased to 6.1 years. Systolic pressure decreased to below 150 mmHg (target level) in 2628 participants (75.0%). During the 4-year open-label follow-up, stroke and cardiovascular complications occurred at similar frequencies in patients formerly randomized to placebo and those continuing active treatment. These rates were similar to those previously observed in the active-treatment group during the double-blind trial. Considering the total follow-up of 4695 randomized patients, immediate compared with delayed anti hypertensive treatment reduced the occurrence of stroke and cardiovascular complications by 28% (P=0.01) and 15% (P=0.03), respectively, with a similar tendency for total mortality (13%, P = 0.09). In 492 diabetic patients, the corresponding estimates of long-term benefit (P < 0.02) were 60, 51 and 38%, respectively. Conclusions Antihypertensive treatment can achieve blood pressure control in most older patients with isolated systolic hypertension. Immediate compared with delayed treatment prevented 17 strokes or 25 major cardiovascular events per 1000 patients followed up for 6 years. These findings underscore the necessity of early treatment of isolated systolic hypertension. J Hypertens 22:847 -857 (C) 2004 Lippincott Williams Wilkins. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|